Biotechnology platform that reverse-engineers immune-activating antigens from patient immune cells to develop personalized vaccines rapidly.
TareBio's platform reads immune cells already fighting a disease in the patient's body and reverse-engineers the antigens that activate them, rather than predicting which antigens might work. This allows development of personalized or population-level vaccines for any cancer or infection in weeks by changing only one input—the immune imprint. The company has run the platform end-to-end and created a vaccine that cured cancer in mice. TareBio is a product of TareBio.